THERAPY WITH GLP-1 AGONISTS AND DIPEPTIDYL-PEPTIDASE IV INHIBITORS IN TYPE 2 DIABETES MELLITUS
Journal Title: Romanian Journal of Diabetes Nutrition and Metabolic Diseases - Year 2011, Vol 18, Issue 4
Abstract
Since type 2 diabetes is increasing and most patients do not reach their therapeutic goals, novel treatment options are needed. The novel therapeutic options for type 2 diabetes mellitus (Type 2 DM); respectively those based on the action of the incretin hormone glucagon-like peptide-1 (GLP-1) were introduced in practice in 2005. Incretin therapies consist in two classes: the injectable GLP-1 receptor agonists only acting on the GLP-1 receptor and dipeptidyl-peptidase inhibitors (DPP-4 inhibitors) as oral medications which increase endogenous GLP-1 and other hormone levels by inhibiting their degradation. In Type 2 DM therapy, incretin-based therapies are attractive and frequently used due to their action and safety profile. Insulin secretion stimulation and glucagon secretion inhibition by the above-mentioned drugs occur in a glucose-dependent manner. However, incretinbased therapies have no risk for hypoglycemias. This review gives data of the mechanism of action of these substances and clinical information.
Authors and Affiliations
Nikos Rigas, Floriana Elvira Ionica, Florica Popescu
Keywords
Related Articles
- EP ID EP140105
- DOI -
- Views 79
- Downloads 0
METABOLIC SYNDROME IN PATIENTS WITH T1DM OLDER THAN 10 YEARS
Metabolic Syndrome (MS) is a clinical entity recently individualized, a clinical concept with multiple definitions that expresses a complex disorder of the body′s energy metabolism, with insulin resistance and compensato...
HIGHLIGHTS FROM THE 47TH ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES
HIGH PREVALENCE OF METABOLIC DISORDERS IN PSORIASIS PATIENTS
Recent studies have shown that psoriasis is a systemic disorder associated with an increased prevalence of metabolic anomalies. This study compares the prevalence of obesity and metabolic disorders in psoriasis patients...
SODIUM-GLUCOSE TRANSPORTER 2 INHIBITION – A POTENTIAL OPTION FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
Glucose homeostasis is maintained by the balanced actions of glucose absorption, gluconeogenesis, glycogenolysis, glucose consumption, glucose excretion and glucose reabsorption. The human kidney is involved in glucose r...
To Be Worthy of the Nobel Prize or to Get the Nobel Prize?